Cognition Therapeutics secured a US patent to 2045 on a new crystalline form of zervimesine (CT1812), an oral candidate aimed at the toxic protein oligomers implicated in dementia with Lewy bodies, Alzheimer's disease and dry age-related macular degeneration. The company is finalizing trial endpoints with the FDA for a registrational study in DLB with psychosis, with manufacturing of the new form planned for early 2027. Evidence remains Phase 2, and no indication is approved.
Key Points
- Zervimesine polymorph patent runs to 2045, extendable five years
- Registrational DLB trial pending FDA endpoint agreement; manufacturing targeted 2027
- Phase 2 data only across DLB, Alzheimer's and dry AMD
Longevity Analysis
Neurodegeneration remains the hardest frontier in extending healthspan, and the strategic value here lies less in the molecule than in what sustains a late-stage program: commercial runway, scalable chemistry, and agreed measures of benefit. Endpoint selection determines whether a drug's effect on cognition, behavior and caregiver burden can be detected at all — a reminder that interpreting a signal correctly is as decisive as producing one. For clinicians advising patients with early cognitive decline, the practical horizon stays unchanged: interference reduction, metabolic and vascular support of brain tissue, and sustained daily practice remain the available levers while registrational data accumulate.
Original published by Longevity.Technology, by Eleanor Garth.